Serum CA 242 and CEA detect different patients with recurrent colorectal cancer

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 981-986

  Carpelan Holmström, Monika A ^a   Haglund, Caj H ^a   Järvinen, Heikki J ^a   Roberts, Peter J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CA 242; Cancer; CEA; Colon; Follow up; Neoplasm; Rectum; Recurrence; Tumour marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ARTICLE; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; TIME FACTORS;

EID: 0029898702     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hine KR and Dykes PW: Serum CEA testing in the post-operative surveillance of colorectal carcinoma. Br J Cancer 49: 689-693, 1984.
2. Kuusela P, Haglund C, and Roberts PJ: Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.Br J Cancer 63: 636-640, 1991.
3. Martin EW, James KK, Hurtubise PE, Catalano P, and Minton JP: The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer 39: 440-446, 1977.
4. Minton JP, Hoehn JL, Gerber DM, Horsley S, Connolly DP, Salwan F, Fletcher W, Cruz AB, Gatchell FG, Oviedo M. Meyer KK, Leffall LD, Berk RS, Stewart PA, and Kurucz SE: Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 55: 1284-1290, 1985.
5. Minton JaNd Chevinsky AH: CEA directed second-look surgery for colon and rectal cancer. Ann Chir Gynaecol 78: 32-37, 1989.
6. Northover J: Carcinoembryonic antigen and recurrent colorectal cancer. Gut 27: 117-122, 1986.
7. Quentmeier A, Schlag P, Smok M, and Herfarth C: Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 16: 319-325, 1990.
8. Roberts PJ: Tumour markers in colorectal cancer. Scand J Gastroenterol 23: 50-58, 1988.
9. Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, and Kieninger G: Eighty-four potential second-look operations based on sequential carcinoelllbryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 149: 198-204, 1985.
10. Sugarbaker PH, Gianola FJ, Dwyer A, and Neuman NR: A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 102: 79-87, 1987.
11. Wanebo HJ, Llaneras M, Martin T, and Kaiser D: Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet 69: 479-487, 1989.
12. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andrén-Sandberg A, and Lindholm L: Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50 and CA19-9. Br J Cancer 65: 215-221, 1992.
13. Carpelan-Holmstrom M, Haglund C, Kuusela P, Järvinen H, and Roberts PJ: Preoperative serum levels of CEA and CA 242 in colorectal cancer. Br J Cancer 71: 868-872, 1995.
14. Lindholm L, Johansson C, Jansson E-L, Hallberg C, and Nilsson O: An immunometric assay (IRMA) for the CA 50 antigen. In: J. Holmgren (ed.) (eds.), Tumour Marker Antigens, pp. 122-133. Lund, Sweden: Studentlitteratur, 1985.
15. Johansson C, Nilsson O, Backström D, Jansson E-L, and Lindholm L: Novel epitopes on the CA50- carrying antigen: Chemical and immunochemical studies,x Tumor Biol 12: 159- 179, 1991.
16. Johansson C, Nilsson O, and Lindholm L: Comparison of serological expression of different epitopes on the CA50 carrying antigen CanAg Int J Cancer 48: 757-763, 1991.
17. Nilsson O, Jansson EL, Johansson C, and Lindholm L: CA 242, a novel tumour-associated carbohydrate antigen with increased tumour specificity and sensitivity. J Tumour Marker Oncol 3: 314, 1988.
18. Gold P and Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and adsorption techniques. J Exp Med 121: 439, 1965.
19. Roberts PJ, Kuusela P, Carpelan-Holmström M, and Haglund C: Value of different tumour markers in colorectal cancer In: R. Klapdor (ed.) (eds.), Tumor Associated Antigens, Oncogens, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties, pp. 30-32. Munchen: Zuckschwerdt Verlag, 1992.
20. Boey J, Cheung HC, Lai CK, and Wong J: A prospective evaluation of serum CEA levels in the management of colorectal carcinoma. World J Surg 8: 279-286, 1984.
21. Carlsson U, Stewenius J, Ekelund G, Leandoer L, and Nosslin B: Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma. Dis Colon rectum 25: 369-373, 1983.
22. Hall NR, Stephenson BM, Purves DA, and Cooper EH: The role of CA242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 70: 549-553, 1994.
23. Denstman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ, and Riether RD: Comparing predictive decision rules in postoperative CEA monitoring. Cancer 58: 2089-2095, 1986.